Next Article in Journal
Early Exercise Protects against Cerebral Ischemic Injury through Inhibiting Neuron Apoptosis in Cortex in Rats
Next Article in Special Issue
PAX2 Expression in Ovarian Cancer
Previous Article in Journal
The Role of Metallothionein in Oxidative Stress
Previous Article in Special Issue
HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines
Int. J. Mol. Sci. 2013, 14(3), 6067-6073; doi:10.3390/ijms14036067
Case Report

A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies

1,* , 1
1 Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan 2 Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama 3591133, Japan
* Author to whom correspondence should be addressed.
Received: 17 February 2013 / Revised: 11 March 2013 / Accepted: 12 March 2013 / Published: 15 March 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
View Full-Text   |   Download PDF [2733 KB, uploaded 19 June 2014]   |   Browse Figures


Ovarian cancer treatment presently does not reflect molecular differences in histologic subtype. Ovarian clear cell carcinoma (OCCC) exhibits several differences in terms of molecular pathogenesis and tumor behavior from the more common, chemosensitive, serous carcinomas, which makes OCCC a candidate for targeted therapies. A 53-year-old Japanese woman was diagnosed with stage IIIc ovarian clear cell adenocarcinoma with marked chemoresistance to conventional regimens. She demonstrated a partial response to a multikinase inhibitor. The tumor was resistant to PI3K/mTOR pathway inhibitors despite harboring a PIK3CA mutation. The present case suggests a role for targeted therapies in the treatment of OCCC and a need for the identification of biomarkers that will predict response to targeted therapies.
Keywords: ovarian clear cell carcinoma; biomarkers; PIK3CA; mTOR inhibitor ovarian clear cell carcinoma; biomarkers; PIK3CA; mTOR inhibitor
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Rahman, M.; Nakayama, K.; Ishibashi, T.; Ishikawa, M.; Rahman, M.T.; Katagiri, H.; Katagiri, A.; Iida, K.; Kikuchi, Y.; Miyazaki, K. A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. Int. J. Mol. Sci. 2013, 14, 6067-6073.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert